MedTrace Logo

Effect of 4 Weeks Fish Oil Supplementation on Cycling Performance in Healthy Male Cyclists

NCT03205241 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-07-02

No results posted yet for this study

Summary

Research Plan

Eleven trained cyclists have completed 4 cycling performance trials, before and after 4 weeks of fish oil supplementation and before and after 4 weeks of placebo with a 4 week washout between supplementation periods. During the performance trials blood, expired air and heart rate were collected. The blood samples have been used to investigate the production of inflammation resulting from the cycling performance test. Inflammation has been assessed using enzyme-linked immunosorbent assay for IL-6, which is an inflammatory cytokine. Work done from the cycling performance will be analysed to investigate whether there is a relationship with power and inflammation and whether this is modulated by fish oil supplementation.

Specific Aims

1. Does 4 weeks of Fish Oil supplementation attenuate the inflammatory response following high intensity cycling.
2. Is a modulation of the inflammatory response connected to cycling performance.

Hypotheses

1. Four weeks of n3-PUFA supplementation will reduce the inflammatory response
2. A reduction in inflammation will improve cycling performance

Anticipated Outcomes

A high level of cycling performance, indicated by a high average power, will be associated with high levels of systemic inflammation. n3-PUFA supplementation will decrease the level of inflammation and consequently cycling performance will be improved.

Conditions

  • Exercise-induced Inflammation

Interventions

DIETARY_SUPPLEMENT

n-3 PUFA

n-3 PUFA capsules containing EPA and DHA

DIETARY_SUPPLEMENT

Placebo

Olive oil capsules

Sponsors & Collaborators

  • University of Worcester

    collaborator OTHER

  • Loughborough University

    lead OTHER

Principal Investigators

  • Lynsey S Wilson, MSc · Loughborough University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-12-31
Completion
2014-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03205241 on ClinicalTrials.gov